transmembrane protein 9Genealiases: DERM4 · TMEM9A
Q-omics provides the consensus-scored TMEM9 profile across patient tissues and cancer cell-line models. TMEM9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM9 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, TMEM9 protein abundance shows 33,772 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KICH, and PDAC as cancer lineages where TMEM9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM9 survival associations across molecular data types. TMEM9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM9 RNA expression–survival associations across cancer types. High TMEM9 expression shows unfavorable associations in HNSC, UVM, KICH, ACC, CESC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM9 RNA expression.
This table summarizes TMEM9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM9 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, KIRC and BLCA. The KICH box plot shows higher TMEM9 RNA expression in normal versus tumor tissue (log2 FC = −2.075, t-test p < 0.001).
This table shows molecular features associated with TMEM9 in patient tissues and cancer cell lines. In patient samples, TMEM9 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
